Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Dec 10:3:e04034.
doi: 10.7554/eLife.04034.

Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Affiliations
Comment

Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

David Blum et al. Elife. .

Abstract

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from "Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion" by Straussman and colleagues, published in Nature in 2012 (Straussman et al., 2012). The key experiments being replicated in this study are from Figure 2A, C, and D (and Supplemental Figure 11) and Figure 4C (and Supplemental Figure 19) (Straussman et al., 2012). Figure 2 demonstrates resistance to drug sensitivity conferred by co-culture with some stromal cell lines and identifies the secreted factor responsible as HGF. In Figure 4, Straussman and colleagues show that blocking the HGF receptor MET abrogates HGF’s rescue of drug sensitivity. The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.

Keywords: RTK inhibitor resistance; Reproducibility Project: Cancer Biology; biochemistry; human; methodology.

PubMed Disclaimer

Conflict of interest statement

DB: This is a Science Exchange associated lab.

RP:CB: EI, FT and JL are employed by and hold shares in Science Exchange Inc.

The other authors declare that no competing interests exist.

Comment on

References

    1. Caenepeel S, Cajulis E, Kendall R, Coxon A, Hughes P. Targeting HGF-mediated resistance to vemurafenib in V600E BRAF mutant melanoma cell lines. 2013 doi: 10.1158/1538-7445.AM2013-3405. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research. Washington, DC. Cancer Res73:Abstract. - DOI
    1. Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Research. 2013;15:R82. doi: 10.1186/bcr3476. - DOI - PMC - PubMed
    1. Cui JJ. Targeting receptor tyrosine kinase MET in Cancer: Small Molecule inhibitors and clinical progress. Journal of Medicinal Chemistry. 2014;57:4427–4453. doi: 10.1021/jm401427c. - DOI - PubMed
    1. Etnyre D, Shambannagari MR, Puri N. Washington, DC: Cancer Research; 2013. Abstract 2078: Synergistic effects of c-Met and BRAF inhibitors and role of c-Met as a therapeutic target in human melanoma. AACR 104th Annual Meeting; 2013.
    1. Faul F, Erdfelder E, Lang AG, Buchner A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods. 2007;39:175–191. doi: 10.3758/BF03193146. - DOI - PubMed

MeSH terms

Substances